Editas Medicine (EDIT) Retained Earnings (2015 - 2025)

Editas Medicine (EDIT) has reported Retained Earnings for 11 consecutive years, with -$1.6 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 10.9% year-over-year to -$1.6 billion; the TTM figure through Dec 2025 stood at -$1.6 billion (down 10.9% YoY), while the FY2025 annual figure was -$1.6 billion, down 10.9% from the prior year.
• Retained Earnings was little changed at -$1.6 billion in Q4 2025 per EDIT's latest filing, from -$1.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$721.9 million in Q1 2021 and bottomed at -$1.6 billion in Q4 2025.
• Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2023.
• Annual changes were most pronounced in 2021 — Retained Earnings slumped 35.44% — and 2025, when it retreated 10.9%.
• Editas Medicine's Retained Earnings stood at -$857.7 million in 2021, then slipped by 25.7% to -$1.1 billion in 2022, then fell by 14.21% to -$1.2 billion in 2023, then slipped by 19.25% to -$1.5 billion in 2024, then declined by 10.9% to -$1.6 billion in 2025.
• Business Quant data shows EDIT's Retained Earnings at -$1.6 billion in Q4 2025, -$1.6 billion in Q3 2025, and -$1.6 billion in Q2 2025.